shire pharmaceuticals group plc <shp.l> out-
LONDON, Jan 17 (Reuters) - Britain's third-biggest drugmaker Shire Pharmaceuticals Group Plc said on Monday that it had out-licensed an experimental treatment for HIV to Avexa Ltd of Australia. The out-licensing of SPD754 is one of the final steps in a divestment programme to allow Shire to focus on later-stage pipeline investment in its core specialism of central nervous system, gastrointestinal and kidney disease, it said in a statement. Shire has been reshaping its business as it looks to reduce reliance on top-selling hyperactivity drug Adderall XR, which accounts for about 50 percent of drug sales but is expected to face competition from cheaper generic copies from 2006 or 2007. "Avexa is an ideal partner for the product," Shire Chief Executive Matthew Emmens said in a statement. "At the same time, we are able to retain a stake in the future value of the product," Emmens added. Avexa will take on responsibility for the global development of SPD754, which is in Phase II clinical trials and is expected to reach the market in 2009. Avexa will have the right to commercialise the treatment throughout the world except in North America, where Shire will retain such rights. Under the deal, Shire will take a A$2 million ($1.52 million) equity stake in Avexa, with an option to acquire 4 million more shares. Shares in Shire closed 0.7 percent higher at 620 pence.
AVX Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held